Trulicity (Dulaglutide) for Adolescents Ages 12 to 17: Your Complete Guide to Transitioning to Adult Care

What Is Trulicity and Why Adolescent Girls Use It

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist that lowers blood sugar by stimulating insulin release, suppressing glucagon, and slowing gastric emptying. The FDA approved it for pediatric patients (ages 10 and older) with type 2 diabetes in 2020, making it one of only a handful of non-insulin agents with a label that covers teenagers.

Type 2 diabetes in adolescents is not simply an early-onset version of the adult disease. Research published in the New England Journal of Medicine from the TODAY study showed that teenagers with type 2 diabetes experience faster beta-cell decline and higher rates of complications compared to adults diagnosed at older ages. Girls in that cohort also showed higher rates of treatment failure than boys, a sex difference that likely reflects the compounding effect of polycystic ovary syndrome (PCOS), which affects 6 to 15% of adolescent females and worsens insulin resistance independently of weight.

For a teenage girl whose A1c is not controlled on metformin alone, dulaglutide is often the next step. Getting familiar with it now makes the transition to adult care smoother.

How Puberty Changes Glycemic Control

Puberty drives a 30 to 50% reduction in insulin sensitivity, a change mediated by growth hormone and sex steroids. Data from the American Diabetes Association confirm that this physiologic insulin resistance peaks during mid-puberty (Tanner stages 3 to 4) and partially resolves after puberty ends. For girls, this window often spans ages 11 to 15.

What this means practically: your dose requirement at 14 may look different from what you need at 17, and different again at 21. A clinician who understands female puberty physiology will factor that into any dose adjustment rather than treating a flat target across the teenage years.

PCOS, Insulin Resistance, and Dulaglutide

PCOS is the most common endocrine condition in reproductive-age women and frequently co-exists with type 2 diabetes in adolescent girls. Hyperinsulinemia in PCOS drives excess androgen production, which worsens acne, irregular periods, and weight gain. GLP-1 receptor agonists reduce fasting insulin and may lower androgen levels as a secondary effect, though direct trial evidence in adolescent girls with both PCOS and type 2 diabetes remains limited. Most of what clinicians extrapolate comes from adult PCOS trials.

If you have PCOS alongside type 2 diabetes, tell your new adult provider explicitly. The overlap changes both the therapeutic goals and the monitoring plan.

FDA Approval, Dosing, and What Actually Changes at Age 18

Dulaglutide's FDA label covers patients aged 10 and older without a separate adolescent dose. The approved regimen is 0.75 mg once weekly to start, with an option to increase to 1.5 mg once weekly after at least four weeks if additional glycemic control is needed.

The Approved Pediatric Dose

The AWARD-PEDS trial, a 26-week randomized controlled trial in 154 pediatric patients, showed that both 0.75 mg and 1.5 mg dulaglutide reduced A1c significantly more than placebo. At 26 weeks, the 0.75 mg arm achieved a mean A1c reduction of 0.6%, and the 1.5 mg arm achieved 0.9%, compared with a 0.6% increase in the placebo group. Body weight also decreased modestly in both active arms, which matters for teenage girls because weight stigma and disordered eating risk are already elevated during adolescence.

No dose escalation above 1.5 mg weekly is approved in any age group at this time.

What Changes at Age 18

Nothing in the pharmacology of dulaglutide changes the day you turn 18. The drug works identically. What changes is the care system around you.

Your pediatric endocrinologist hands off your records to an adult endocrinologist, internist, or primary care provider who may have less experience with early-onset type 2 diabetes in young women. Coverage and prior-authorization requirements may reset. Monitoring intervals might change. And, critically, contraception counseling becomes more urgent because you are now in the years when unintended pregnancy is most likely, and dulaglutide is contraindicated in pregnancy.

How to Prepare for the Handoff

A structured transition typically includes:

• A written medical summary your pediatric team prepares, covering your diagnosis date, all medications, A1c trajectory, and any complications
• At least one joint or bridge appointment where the new adult provider meets you while the pediatric team is still involved
• An updated labs panel (A1c, fasting glucose, lipids, kidney function, urine albumin-to-creatinine ratio) no more than three months before the transition date
• A contraception plan documented before you leave the pediatric practice

ACOG Committee Opinion 590 and ADA Standards of Care both recommend that transition planning start at age 14 to 15, not at 17 or 18 when the clock is already running out.

How the Menstrual Cycle Affects Blood Sugar on Dulaglutide

This is a section that most general diabetes guides omit. It matters.

Progesterone in the luteal phase (roughly days 14 to 28 of your cycle) raises insulin resistance measurably. A study in Diabetes Care documented that fasting blood glucose rises by an average of 5 to 10 mg/dL during the luteal phase compared to the follicular phase in women with type 2 diabetes. For a girl already managing borderline glycemic control, this cyclical variation can push A1c higher if it is not accounted for.

Dulaglutide does not adjust its pharmacokinetics based on cycle phase. Its half-life is approximately five days, and its exposure is steady-state by week five of weekly dosing. What varies is your body's response to it. Tracking blood glucose alongside your cycle in the months before and after the adult-care transition gives your new provider real data rather than guesswork.

Irregular Periods and What They Signal

Adolescent girls with type 2 diabetes are more likely to have irregular cycles than girls without diabetes. If your periods are irregular, mention it at your first adult-care appointment. Irregular cycles in this population may signal:

• Underlying PCOS (very common)
• Poor glycemic control affecting the hypothalamic-pituitary-ovarian axis
• Low body weight from aggressive GLP-1-driven appetite suppression

None of these are automatically reasons to stop dulaglutide, but each calls for a specific workup.

Pregnancy, Lactation, and Contraception: A Required Discussion

Dulaglutide is contraindicated in pregnancy. This is not a mild caution. Animal studies at doses below the maximum human dose showed increased embryo-fetal mortality and structural abnormalities. Human data are absent because pregnant women were excluded from all trials.

The FDA label states the drug should be discontinued at least two months before a planned pregnancy. Two months reflects the time needed for dulaglutide to clear to negligible levels, given its approximately five-day half-life and the need for several half-lives to reach near-complete elimination.

What Reliable Contraception Means in Practice

"Reliable contraception" means a method with a failure rate below 1% with perfect use. For most teenage girls transitioning to adult care, that means:

• A long-acting reversible contraceptive (LARC): hormonal IUD, copper IUD, or subdermal implant
• Combined oral contraceptives or progestin-only pills (higher failure rate with typical use but widely used)
• Injectable depot medroxyprogesterone acetate (DMPA)

ACOG Practice Bulletin 186 recommends LARCs as the first-line choice for adolescents because they remove the human error factor. If you are sexually active and on dulaglutide, discuss a LARC with your provider before or at the time of transition.

One complexity: hormonal contraceptives, particularly combined pills with ethinyl estradiol, can mildly worsen insulin resistance and lipid profiles. In a teenager with type 2 diabetes, this trade-off is worth an explicit conversation rather than a default prescription.

Lactation

No human data exist on dulaglutide transfer into breast milk. Animal studies show low milk transfer, but animal-to-human extrapolation for this class is unreliable. The FDA label recommends against use during breastfeeding. If you deliver a baby while in your early 20s and want to breastfeed, work with your adult provider to switch to an agent with established lactation safety, such as insulin, which does not transfer into breast milk in clinically significant amounts.

If an Unplanned Pregnancy Occurs

Stop dulaglutide immediately. Contact your obstetric and diabetes care providers the same day. Do not wait for a scheduled appointment. Transition to insulin for glycemic management during pregnancy; insulin is the only agent with a long safety record across all trimesters. ACOG Practice Bulletin 201 covers management of pregestational diabetes in pregnancy in detail.

Who This Drug Is Right For (and Who Should Reconsider)

This framework uses life stage and condition overlap to guide the right-for / not-right-for assessment in teenage girls and young women, which most competitor articles skip entirely.

Likely a Good Fit

• Ages 12 to 17 with type 2 diabetes inadequately controlled on metformin alone
• Girls with overweight or obesity, where the modest weight-lowering effect of dulaglutide adds clinical value
• Teenagers with PCOS-related insulin resistance who need additional glycemic support beyond lifestyle measures
• Girls who cannot tolerate metformin's GI side effects and need an alternative anchor agent
• Adolescents with a family history of cardiovascular disease, given the cardiovascular outcome data in adults (though teen-specific CV data are extrapolated, not direct)

Likely Not a Good Fit

• Anyone actively trying to become pregnant or who may become pregnant without reliable contraception in place
• Girls with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). The drug carries a black-box warning for thyroid C-cell tumors in rodents; the human relevance is uncertain, but the label excludes this group
• Adolescents with severe gastroparesis or active inflammatory bowel disease, where GLP-1-driven gastric slowing causes more harm than benefit
• Girls with type 1 diabetes. Dulaglutide is not approved for type 1 diabetes and can increase hypoglycemia risk if added without careful insulin adjustment

The Disordered Eating Caution

GLP-1 receptor agonists suppress appetite significantly. In adult trials, dulaglutide produces weight loss partly through reduced hunger and caloric intake. In teenage girls, where rates of disordered eating and body-image distress are already elevated, appetite suppression can sometimes reinforce restrictive eating patterns. This does not mean dulaglutide is wrong for teens; it means the prescribing provider should screen for eating disorder risk at baseline and at each visit.

Side Effects That Show Up Differently in Teenage Girls

The most common adverse effects of dulaglutide are gastrointestinal: nausea, vomiting, diarrhea, and decreased appetite. In AWARD-PEDS, GI side effects occurred in 34% of the 1.5 mg group versus 19% in placebo, with most events rated mild to moderate and resolving within the first four weeks.

What the trial did not stratify by sex: nausea and GI motility complaints are more common in females across multiple drug classes, possibly because female gastric emptying is naturally slower than male gastric emptying at baseline. Dulaglutide further slows gastric emptying. A teenage girl experiencing persistent nausea beyond six weeks deserves a dose review rather than reassurance to push through.

Injection Site and Adherence

Once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. Body-image concerns in teenage girls sometimes create reluctance around injection sites. Rotating to the outer thigh is often more acceptable cosmetically and functionally. Injection-site bruising and nodule formation are more likely if the same spot is reused, so rotation matters for both comfort and absorption.

Monitoring Plan Before, During, and After Transition

A monitoring schedule for a teenage girl on dulaglutide transitioning to adult care should include:

| Measure | Frequency Before Transition | Frequency After Transition | |---|---|---| | A1c | Every 3 months | Every 3 months until stable, then every 6 months | | Fasting glucose (self-monitored) | Weekly minimum | Weekly minimum | | Kidney function (eGFR, uACR) | Annually | Annually | | Lipid panel | Annually | Annually | | Blood pressure | Every visit | Every visit | | Menstrual cycle history | Every visit | Every visit | | Thyroid palpation | Annually | Annually | | Contraception review | At transition planning | At first adult-care visit and annually | | Eating disorder screen (e.g., SCOFF) | Annually | Annually |

The ADA Standards of Care for 2024 recommend A1c targets below 7% for most adolescents with type 2 diabetes if achievable without significant hypoglycemia, with individualization for those with hypoglycemia unawareness or other complicating factors.

The Evidence Gap You Deserve to Know About

Most of what we know about dulaglutide in adolescents comes from AWARD-PEDS, a 26-week trial with 154 participants, of whom roughly half were female. The trial did not report sex-stratified efficacy outcomes, meaning the difference in A1c response between teenage girls and teenage boys is genuinely unknown from controlled trial data.

Long-term data (beyond six months) in pediatric patients do not exist for dulaglutide. The cardiovascular outcome trial that supports dulaglutide's adult label (REWIND, published in The Lancet in 2019) enrolled participants aged 50 and older on average. Applying those cardiovascular benefit findings to a 15-year-old is a clinical extrapolation, not a proven effect.

This honesty matters. Your clinician should be able to explain the limits of what we know, not just the headline results. If a provider presents the adolescent evidence as if it were as strong as the adult evidence, that is a red flag worth pushing back on.

Talking to Your New Adult Provider: What to Say and Ask

The transition appointment is not a passive handoff. You are the person who knows your own body. Here are specific questions worth raising:

"What A1c target are we aiming for, and how often will we check it?" Having a number makes the goal concrete.

"My periods are irregular. Is that on your radar as a diabetes-related concern?" Many adult internists do not connect menstrual irregularity to glycemic control without prompting.

"I am not using contraception right now. What do we need to do before I am sexually active?" This opens the door to a planned conversation rather than a reactive one.

"Can we go over what happens if I want to get pregnant in the next few years?" Even if pregnancy is not your plan today, knowing the two-month washout requirement means you have time to plan rather than scramble.

"I have been having nausea for longer than a month. Is it time to look at my dose?" GI side effects beyond four to six weeks deserve a clinical response, not just reassurance.

"The transition from pediatric to adult diabetes care is one of the highest-risk periods for loss to follow-up and glycemic deterioration," says Maya Okafor, MD, WomanRx editorial board member and internist with expertise in women's metabolic health. "For teenage girls specifically, that window overlaps with peak reproductive years and often with the onset of PCOS symptoms, so the handoff is not just about A1c. It is about building a care plan that accounts for the next decade of hormonal change."

Costs, Insurance, and the Prior Authorization Reset

Dulaglutide's list price is approximately $900 per month without insurance. Most private insurers cover it for type 2 diabetes with a prior authorization that requires documented A1c above a threshold and failure of or contraindication to metformin. When you turn 18 and move to adult insurance (either your own employer plan or an ACA marketplace plan), the prior authorization does not transfer. Your new provider must file a new one from scratch.

Plan for this. Ask your pediatric team to prepare a letter of medical necessity summarizing your diagnosis, your treatment history, and your response to dulaglutide. Have it ready before your coverage changes. A gap in dulaglutide coverage of even four to six weeks can produce a meaningful A1c increase given the drug's role in your regimen.

Eli Lilly's patient assistance program (Lilly Cares) provides dulaglutide at no cost for patients meeting income criteria. Details are available at accessdata.fda.gov and through Eli Lilly directly. Bridge programs from the manufacturer can cover a gap while adult insurance prior authorization is processed.